MARKET

PTN

PTN

PALATIN TECH
AMEX

Real-time Quotes | Nasdaq Last Sale

0.5280
-0.0047
-0.88%
After Hours: 0.5400 +0.012 +2.27% 17:58 05/11 EDT
OPEN
0.5010
PREV CLOSE
0.5327
HIGH
0.5525
LOW
0.5010
VOLUME
1.53M
TURNOVER
--
52 WEEK HIGH
1.300
52 WEEK LOW
0.3750
MARKET CAP
121.47M
P/E (TTM)
-4.6809
1D
5D
1M
3M
1Y
5Y
Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor
Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the a...
GlobeNewswire · 1d ago
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 5d ago
BRIEF-Palatin Announces U.S. Patent Term Extension For Vyleesi® (Bremelanotide Injection)
reuters.com · 05/04 11:32
Palatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection)
CRANBURY, N.J., May 4, 2021 /PRNewswire via COMTEX/ -- CRANBURY, N.J., May 4, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a...
PR Newswire - PRF · 05/04 11:30
Global Lifestyle Drugs Market Size 2021 with a CAGR of 2.87%, Research by Business Opportunities, Top Companies data report covers are Allergan, BMS, Eli Lilly
The Express Wire · 04/29 06:00
Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
PR Newswire · 04/20 12:30
Palatin Announces Two Presentations At 2021 Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting May 1-7
Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today
Benzinga · 04/20 11:38
Global Melanocyte Stimulating Hormone Receptor Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Melanocyte Stimulating Hormone Receptor market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 04/15 16:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTN. Analyze the recent business situations of PALATIN TECH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTN stock price target is 2.333 with a high estimate of 3.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 44.69M
% Owned: 19.43%
Shares Outstanding: 230.05M
TypeInstitutionsShares
Increased
32
4.81M
New
20
1.36M
Decreased
17
1.34M
Sold Out
6
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Independent Director
John Prendergast
President/Chief Executive Officer/Director
Carl Spana
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
Stephen Wills
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
stephen Wills
Independent Director
Robert deVeer
Independent Director
Alan Dunton
Independent Director
Joseph Hull
Independent Director
Anthony Manning
Independent Director
Arlene Morris
No Data
About PTN
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.

Webull offers kinds of Palatin Technologies, Inc. stock information, including AMEX:PTN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTN stock methods without spending real money on the virtual paper trading platform.